When comparing HRD-LOH scores between BRCA1 and BRCA2 mutated tumours in both breast and ovarian cohorts (Supplementary Fig. 3), an analysis not performed in the smaller TCGA dataset, the scores were slightly higher for BRCA1 compared with BRCA2 for both tumour types. The gene discussed is BRCA1; the disease is neoplasm.